版本:
中国

BRIEF-Rexahn Pharmaceuticals presents preliminary efficacy data from phase Ib/IIa trial of RX-3117, Supinoxin phase I trial

Oct 10 Rexahn Pharmaceuticals Inc :

* Rexahn Pharmaceuticals presents preliminary efficacy data from phase Ib/IIa trial of RX-3117 in metastatic pancreatic cancer and supinoxin phase I trial at 2016 European Society For Medical Oncology (ESMO) congress

* Rexahn Pharmaceuticals Inc - since predefined efficacy criteria have been achieved, stage 2 of study has been initiated

* Rexahn Pharmaceuticals Inc - RX-3117 was shown to be safe and well tolerated in the patient group Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐